Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation

被引:78
作者
Ikezoe T. [1 ]
机构
[1] Department of Hematology and Respiratory Medicine, Kochi University, Nankoku, Kochi
基金
日本学术振兴会;
关键词
Activated protein C; Disseminated intravascular coagulation; Sepsis; Thrombomodulin;
D O I
10.1186/s40560-014-0050-7
中图分类号
学科分类号
摘要
The thrombomodulin (TM)/activated protein C (APC) system plays an important role in maintaining the homeostasis of thrombosis and hemostasis and maintaining vascular integrity in vivo. TM expressed on vascular endothelium binds to thrombin, forming a 1:1 complex and acts as an anticoagulant. In addition, the thrombin-TM complex activates protein C to produce APC, which inactivates factors VIIIa and Va in the presence of protein S, thereby inhibiting further thrombin formation. Intriguingly, APC possesses anti-inflammatory as well as cytoprotective activities. Moreover, the extracellular domain of TM also possesses APC-independent anti-inflammatory and cytoprotective activities. Of note, the TM/APC system is compromised in disseminated intravascular coagulation (DIC) caused by sepsis due to various mechanisms, including cleavage of cell-surface TM by exaggerated cytokines and proteases produced by activated inflammatory cells. Thus, it is reasonable to assume that reconstitution of the TM/APC system by recombinant proteins would alleviate sepsis and DIC. On the basis of the success of the Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial, the FDA approved the use of recombinant human APC (rhAPC) for severe sepsis patients in 2002. However, subsequent clinical trials failed to show clinical benefits for rhAPC, and an increased incidence of hemorrhage-related adverse events was noted, which prompted the industry to withdraw rhAPC from the market. On the other hand, recombinant human soluble TM (rTM) has been used for treatment of individuals with DIC since 2008 in Japan, and a phase III clinical trial evaluating the efficacy of rTM in severe sepsis patients with coagulopathy is now ongoing in the USA, South America, Asia, Australia, European Union, and other countries. This review article discusses the molecular mechanisms by which the TM/APC system produces anticoagulant as well as anti-inflammatory and cytoprotective activities in septic DIC patients. © 2015 Ikezoe;
引用
收藏
相关论文
共 72 条
[1]  
Gando S., Saitoh D., Ogura H., Mayumi T., Koseki K., Ikeda T., Ishikura H., Iba T., Ueyama M., Eguchi Y., Ohtomo Y., Okamoto K., Kushimoto S., Endo S., Shimazaki S., Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey, Crit Care Med, 36, pp. 145-150, (2008)
[2]  
Ruf W., Edgington T.S., Structural biology of tissue factor, the initiator of thrombogenesis in vivo, FASEB J, 8, pp. 385-390, (1994)
[3]  
Levi M., Keller T.T., van Gorp E., ten Cate H., Infection and inflammation and the coagulation system, Cardiovasc Res, 60, pp. 26-39, (2003)
[4]  
Zeerleder S., Hack C.E., Wuillemin W.A., Disseminated intravascular coagulation in sepsis, Chest, 128, pp. 2864-2875, (2005)
[5]  
Semeraro N., Ammollo C.T., Semeraro F., Colucci M., Sepsis, thrombosis and organ dysfunction, Thromb Res, 129, pp. 290-295, (2012)
[6]  
Ichinose A., Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control, Int J Hematol, 95, pp. 362-370, (2012)
[7]  
Harris H.E., Raucci A., Alarmin(g) news about danger: workshop on innate danger signals and HMGB1, EMBO Rep, 8, pp. 774-778, (2006)
[8]  
Allam R., Kumar S.V., Darisipudi M.N., Anders H.J., Extracellular histones in tissue injury and inflammation, J Mol Med, 92, pp. 465-472, (2014)
[9]  
Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T., Junger W., Brohi K., Itagaki K., Hauser C.J., Circulating mitochondrial DAMPs cause inflammatory responses to injury, Nature, 464, pp. 104-107, (2010)
[10]  
Fiuza C., Bustin M., Talwar S., Tropea M., Gerstenberger E., Shelhamer J.H., Suffredini A.F., Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells, Blood, 101, pp. 2652-2660, (2003)